GLP-1 Medications vs.
SGLT2 Inhibitors: How They Differ

Different mechanisms, different practical questions

Semaglutide is a GLP-1 receptor agonist. Its FDA label says it increases insulin and lowers glucagon when glucose is high, and modestly delays early post-meal stomach emptying. Gastrointestinal effects and some oral-medicine questions therefore matter in this group.^[3]

Tirzepatide should not be described as GLP-1-only. The Mounjaro and Zepbound labels identify it as a glucose-dependent insulinotropic polypeptide (GIP) receptor and GLP-1 receptor agonist. It is useful shorthand to call it “GLP-1–based,” but decisions still require the exact product and label.^{[2] [5]}

SGLT2 in the kidney’s proximal tubules normally reabsorbs much filtered glucose. Dapagliflozin blocks it, so more glucose is excreted in urine; its label also describes reduced sodium reabsorption. This differs from incretin-receptor activation and brings different monitoring questions.^[6]

Type 2 diabetes is shared territory, but labels are product-specific

Several products in both groups are approved for type 2 diabetes in defined populations. Ozempic is approved for adult glycemic control and has product-specific cardiovascular and kidney risk-reduction indications. Oral Rybelsus and Ozempic tablets are approved for adult glycemic control and major-cardiovascular-event reduction in adults at high cardiovascular risk. Mounjaro is approved for glycemic control in adults and children age 10 and older.^{[3] [4] [5]}

Farxiga, Jardiance, and Invokana each have a type 2 diabetes glycemic-control indication. Their labels say not to use them for that purpose in type 1 diabetes, and kidney-function limits differ: Farxiga’s label uses eGFR below 45 mL/min/1.73 m², while the reviewed Jardiance and Invokana labels use below 30. A prescriber must interpret those facts in context.^{[6] [7] [8]}

Heart, kidney, and heart-failure decisions require the exact indication

For type 2 diabetes plus cardiovascular or kidney disease, the label and condition can matter as much as glucose lowering. Ozempic includes reduced major-cardiovascular-event risk in adults with established cardiovascular disease and specified kidney/CV risk reduction in adults with chronic kidney disease. Oral semaglutide tablets include a major-cardiovascular-event indication for adults at high cardiovascular risk.^{[3] [4]}

Some SGLT2 indications reach beyond type 2 diabetes. Farxiga has specified CKD and heart-failure risk-reduction uses; Jardiance has specified heart-failure and CKD uses. Invokana instead specifies adults with type 2 diabetes plus established cardiovascular disease for one outcome indication and diabetic nephropathy with albuminuria for another. “An SGLT2” is not a sufficient prescription description.^{[6] [7] [8]}

ADA recommends an SGLT2 inhibitor for type 2 diabetes with heart failure, and an SGLT2 inhibitor or GLP-1 receptor agonist with demonstrated benefit for many adults with chronic kidney disease. For established or high-risk atherosclerotic cardiovascular disease, it calls for a GLP-1 receptor agonist and/or SGLT2 inhibitor with demonstrated benefit.^[10]

Weight effects are not the same as an obesity indication

Wegovy and Zepbound are FDA-approved finished products for chronic weight management under their own labels; Zepbound also treats moderate-to-severe OSA in adults with obesity, while Wegovy has its own cardiovascular-risk-reduction indication in adults with known heart disease and obesity or overweight. Do not transfer these labels to diabetes-only products.^{[1] [2]}

NIDDK says GLP-1 receptor agonists may make people feel less hungry and help some people lose weight. SGLT2 trials may report body-weight changes, but reviewed Farxiga, Jardiance, and Invokana labels are not obesity-drug labels. SGLT2 products should not be presented as obesity medicines.^{[6] [7] [8] [9]}

Safety questions differ—and are not complete checklists

For semaglutide and tirzepatide products discussed here, a personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN 2), or serious hypersensitivity can be contraindications. Labels also address pancreatitis, gallbladder disease, severe GI reactions, volume-depletion-related acute kidney injury, and hypersensitivity. Semaglutide labels address diabetic-retinopathy complications, and delayed stomach emptying can matter for other oral medicines.^{[1] [2] [3] [4] [5]}

SGLT2 labels warn about ketoacidosis, which can occur below the glucose level people may expect. Farxiga and Jardiance list reduced insulin, illness, reduced food intake, a ketogenic diet, surgery, volume depletion, and alcohol abuse as triggers. They also warn about volume depletion and urinary or genital infections, including rare serious infections. Review illness, procedure, hydration, and medication questions with a clinician or pharmacist rather than changing a prescription alone.^{[6] [7]}

Invokana additionally includes lower-limb amputation and fracture warnings. It would be inaccurate to assign that warning set to every SGLT2 product. Both classes can raise hypoglycemia questions with insulin or an insulin secretagogue.^{[6] [7] [8]}

Can a clinician use both?

Sometimes. ADA discusses GLP-1 receptor agonist/SGLT2 inhibitor combination therapy in selected type 2 diabetes settings. The choice considers heart, kidney, and weight goals; other conditions; safety; tolerability; and access. It is not a reason for everyone to add another medicine.^[10]

A 2025 systematic review and meta-analysis of cohort studies characterized combination effects as uncertain. Observational comparisons cannot prove additive benefit for each person. Discuss the exact labeled product, monitoring, adverse effects, interactions, and reassessment plan with the clinician.^[12]

Approved branded finished products are not compounded preparations

The product labels and trials cited here concern FDA-approved branded finished products. FDA says compounded GLP-1 drugs are not FDA approved and do not undergo FDA review for safety, effectiveness, or quality before marketing. FDA says compounded drugs should be used only when a patient’s medical needs cannot be met by an FDA-approved drug. Branded-product evidence does not establish a compounded preparation’s quality, bioequivalence, safety, effectiveness, or outcomes.^[11]

For related education, read what semaglutide is, GLP-1 real-world effectiveness, or Luma’s treatment information.

Frequently asked questions